

From: [REDACTED]
To: [REDACTED]
Cc: [REDACTED]
Subject: Monash IVF Non-invasive preimplantation genetic testing for aneuploidy [SEC=OFFICIAL]
Date: Wednesday, 13 January 2021 3:56:58 PM

Dear [REDACTED]

I am writing to acknowledge receipt of [REDACTED] letter dated 5 January 2021 regarding the suspensions of Monash IVF's non-invasive preimplantation genetic testing for aneuploidy. I understand you will be progressing the investigation once [REDACTED] requested I provide any information to you.

In regard to [REDACTED] request, we will advise [REDACTED] of the outcome of our investigation once it is complete, including a summary of the findings. If you have any questions please feel free to contact me.

Kind regards,

[REDACTED]

[REDACTED]
[REDACTED]

Devices Post Market Monitoring Section
Medical Devices Surveillance Branch

Phone: [REDACTED]
Email: [REDACTED]

Therapeutic Goods Administration
Department of Health
PO Box 100
Woden ACT 2606
www.tga.gov.au

For ongoing information and updates please subscribe to the TGA's [Medical Devices Information](#) and [IVDs Information](#) email subscription services.

[REDACTED]

This response is general information given to you without prejudice; it is not binding on the TGA and you should get your own independent legal advice to ensure that all of the legislative requirements are met.

Important: This transmission is intended only for the use of the addressee and may contain confidential or legally privileged information. If you are not the intended recipient, you are notified that any use or dissemination of this communication is strictly prohibited. If you receive this transmission in error please notify the author immediately and delete all copies of this transmission